The number of PCNA-positive cells was significantly lower in paclitaxel-treated SKOV3ip1 tumors than in control mice (64.4 ± 17.3 vs 108.4 ± 24.7, P < .01), whereas no significant reduction was observed in response to rhLK8 treatment (74.0 ± 17.6 vs 108.4 ± 24.7, P > .05). The most significant decrease in the number of PCNA-positive cells was observed

in SKOV3ip1 tumors treated with the combination of paclitaxel and rhLK8 (41.0 ± 12.8 vs 108.4 ± 24.7, P < .01; www.selleckchem.com/products/dinaciclib-sch727965.html Table 2 and Figure 1A). In HeyA8 tumors, treatment with paclitaxel or rhLK8 alone did not significantly decrease the number of PCNA-positive cells (88.6 ± 16.9 vs 98.4 ± 16.1, P > .05 and 76.1 ± 20.0 vs 98.4 ± 16.1, P > .05, respectively); however, combination treatment significantly reduced the number of PCNA-positive cells (55.9

± 14.2 vs 98.4 ± 16.1, P < .01; Table 2 and Figure 1B). No significant differences in MVD were detected between control and paclitaxel-treated PD0332991 order SKOV3ip1 tumors (84.0 ± 27.5 vs 73.1 ± 20.4, P > .05); however, treatment with rhLK8 alone and, in particular, the combination of rhLK8 and paclitaxel significantly decreased MVD in SKOV3ip1 tumors as compared with the controls (44.0 ± 9.7 vs 84.0 ± 27.5, P < .01 and 29.4 ± 5.7 vs 84.0 ± 27.5, P < 0.01, respectively; Table 2 and Figure 2A). In HeyA8 tumors, MVD was significantly reduced by treatment with paclitaxel compared with the control group (40.0 ± 15.7 vs 57.1 ± 18.5, P < .05) and to a greater extent with rhLK8 alone (27.0 ± Carnitine palmitoyltransferase II 6.1 vs 57.1 ± 18.5, P < .01) or the combination of paclitaxel and rhLK8 (14.3 ± 5.0 vs 57.1 ± 18.5, P < .001; Table 2 and Figure 2B). Immunofluorescence double staining of CD31 (red) and TUNEL (green) was performed to evaluate apoptosis of tumor cells and tumor-associated endothelial cells in response to the different treatments. Apoptosis of endothelial cells is indicated by co-localization, detected by a yellow signal. In SKOV3ip1 tumors (Table 2 and Figure 3A), few tumor cells or tumor-associated endothelial cells were apoptotic in the control group.

Paclitaxel treatment significantly induced apoptosis in tumor-associated endothelial cells compared with the control group (4.0 ± 2.1 vs 0.6 ± 1.0, P < .05). A more significant increase in apoptosis was induced by rhLK8 alone (11.7 ± 4.0 vs 0.6 ± 1.0; P < .01), and the combination of the two drugs enhanced this effect (31.3 ± 9.4 vs 0.6 ± 1.0, P < .001). A similar trend was observed in HeyA8 tumors ( Table 2 and Figure 3B), in which paclitaxel significantly induced apoptosis compared to the control group (2.7 ± 1.6 vs 0.2 ± 0.4, P < .05), and the effect was enhanced by rhLK8 (7.3 ± 3.4 vs 0.2 ± 0.4, P < .01) or the combination of the two drugs (26.4 ± 10.2 vs 0.2 ± 0.4, P < .001). In the SKOV3ip1 and HeyA8 tumor models, apoptosis of tumor cells was induced only in the paclitaxel treatment group and not in the rhLK8 treatment group, whereas the combination of paclitaxel and rhLK8 intensified the apoptosis of tumor cells ( Figure 3).